Education
About Us
Working with TipRanks
Follow Us
Xspray Pharma AB (SE:XSPRAY)
:XSPRAY
XSPRAY Stock Chart & Stats
kr31.20
kr0.60(1.95%)
At close: 4:00 PM EST
kr31.20
kr0.60(1.95%)
Day’s Range― - ―
52-Week Rangekr22.59 - kr64.10
Previous CloseN/A
Volume2.99K
Average Volume (3M)297.70K
Market Cap
kr1.16B
Enterprise Valuekr1.08B
Total Cash (Recent Filing)kr153.75M
Total Debt (Recent Filing)kr170.11M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding41,742,340
10 Day Avg. Volume602,659
30 Day Avg. Volume297,696
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-6.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary HyNap Formulation PlatformHyNap is a platform technology that improves bioavailability and enables differentiated dosage forms. A reusable platform creates durable competitive advantage across multiple small‑molecule candidates, supports repeat partnerships and licensing, and scales technical know‑how over years.
Focus On Reformulating Established DrugsTargeting established small molecules reduces discovery risk and shortens development timelines versus novel drug discovery. This strategy increases probability of regulatory progress, makes out‑licensing and milestone revenue more attainable, and is structurally attractive to partners.
Sizable Equity Base Provides Financial BufferEquity of ~604.6M versus assets gives a meaningful capital buffer, supporting ongoing R&D and partnership activity without immediate insolvency risk. This balance sheet strength preserves strategic optionality for 2–6 months and improves ability to absorb near‑term setbacks.
Bears Say
No Revenue And Sustained Net LossesAbsence of commercial revenue for multiple years means operations rely entirely on financing or partner deals. Persistent losses erode equity over time and reduce self‑funding ability, increasing dependency on external capital and dilutive financings unless commercial sales commence.
Worsening Operating Cash Flow / Heavy Cash BurnRapidly widening negative operating cash flow signals escalating burn from development activities. This creates structural runway pressure, forces frequent financing or deal‑making, and can constrain R&D pacing and negotiation leverage with partners over the medium term.
Rising Debt Increases Leverage And Fixed ObligationsMaterial increase in debt raises fixed repayment and covenant risk, reducing financial flexibility. Higher leverage amplifies refinancing and interest‑rate exposure and limits ability to fund R&D or weather trial delays without additional dilutive or restrictive financing.
Xspray Pharma AB News
XSPRAY FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr22.59 and its highest was kr64.10 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr1.16B.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is May 06, 2026 which is in 77 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Feb 12, 2026. The company reported -kr0.886 earnings per share for the quarter, missing the consensus estimate of kr1.754 by -kr2.64.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 41,742,340 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -kr0.886 in its last earnings report, missing expectations of kr1.754. Following the earnings report the stock price went up 4.348%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---